Table 1 Clinical characteristics
Overall | Surgical intervention | Catheter intervention | Thrombolytic therapy | Anticoagulation only | |
|---|---|---|---|---|---|
Number | 76 | 16 | 16 | 16 | 28 |
Baseline characteristics | |||||
Gender, male | 34 (44.7%) | 5 (31.3%) | 7 (43.8%) | 9 (56.3%) | 13 (46.4%) |
Age (years) | 58.4 ± 14.3 | 61.7 ± 11.8 | 55.5 ± 14.8 | 59.6 ± 17.1 | 57.6 ± 14.0 |
BMI (kg/m2) | 24.3 ± 4.5 | 24.7 ± 4.5 | 23.8 ± 4.2 | 23.8 ± 4.0 | 24.7 ± 5.0 |
BMI ≥ 30 kg/m2 | 7 (9.2%) | 2 (12.5%) | 0 (0.0%) | 0 (0.0%) | 5 (17.9%) |
Comorbidity | |||||
History of VTE | 4 (5.3%) | 0 (0.0%) | 1 (6.3%) | 2 (12.5%) | 1 (3.6%) |
History of PE | 2 (2.6%) | 0 (0.0%) | 0 (0.0%) | 1 (6.3%) | 1 (3.6%) |
History of DVT | 4 (5.3%) | 0 (0.0%) | 1 (6.3%) | 2 (12.5%) | 1 (3.6%) |
Chronic heart disease | 11 (14.5%) | 2 (12.5%) | 5 (31.3%) | 2 (12.5%) | 2 (7.1%) |
History of stroke | 2 (2.6%) | 0 (0.0%) | 1 (6.3%) | 1 (6.3%) | 0 (0.0%) |
COPD/asthma | 4 (5.3%) | 0 (0.0%) | 2 (12.5%) | 0 (0.0%) | 2 (7.1%) |
History of major bleeding | 5 (6.6%) | 2 (12.5%) | 1 (6.3%) | 1 (6.3%) | 1 (3.6%) |
Hypertension | 32 (42.1%) | 4 (25.0%) | 7 (43.8%) | 9 (56.3%) | 12 (42.9%) |
Diabetes | 11 (14.5%) | 0 (0.0%) | 3 (18.8%) | 3 (18.8%) | 5 (17.9%) |
Dyslipidemia | 13 (17.1%) | 2 (12.5%) | 3 (18.8%) | 3 (18.8%) | 5 (17.9%) |
Chronic kidney disease | 14 (18.4%) | 2 (12.5%) | 3 (18.8%) | 4 (25.0%) | 5 (17.9%) |
Dialysis | 1 (1.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (3.6%) |
Autoimmune disease | 2 (2.6%) | 0 (0.0%) | 1 (6.3%) | 0 (0.0%) | 1 (3.6%) |
Congenital coagulation defects | 7 (9.2%) | 0 (0.0%) | 1 (6.3%) | 3 (18.8%) | 3 (10.7%) |
Active cancer | 6 (7.9%) | 2 (12.5%) | 1 (6.3%) | 0 (0.0%) | 3 (10.7%) |